Diabetes - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols NGFR and NTRK2	Name 1 nerve growth factor receptor	Name2 neurotrophic receptor tyrosine kinase 2	Pathway 1 Axonal growth inhibition (RHOA activation) NRAGE signals death through JNK p75NTR negatively regulates cell cycle via SC1 Ceramide signalling Regulated proteolysis of p75NTR NFG and proNGF binds to p75NTR NADE modulates death signalling NRIF signals cell death from the nucleus NRIF signals cell death from the nucleus p75NTR recruits signalling complexes p75NTR recruits signalling complexes NF-kB is activated and signals survival Axonal growth stimulation	Pathway 2 PIP3 activates AKT signaling NGF-independant TRKA activation Constitutive Signaling by Aberrant PI3K in Cancer PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling BDNF activates NTRK2 (TRKB) signaling NTF3 activates NTRK2 (TRKB) signaling NTF4 activates NTRK2 (TRKB) signaling Activated NTRK2 signals through RAS Activated NTRK2 signals through PLCG1 Activated NTRK2 signals through PLCG1 Activated NTRK2 signals through PI3K Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK2 signals through FYN NTRK2 activates RAC1 NTRK2 activates RAC1 Activated NTRK2 signals through CDK5	Drugs 1	Drugs 2 Amitriptyline Esketamine Entrectinib Fostamatinib Larotrectinib	Diseases 1	Diseases 2 Neuroblastoma
Novel Novel	Symbols NGFR and SORT1	Name 1 nerve growth factor receptor	Name2 sortilin 1	Pathway 1 Axonal growth inhibition (RHOA activation) NRAGE signals death through JNK p75NTR negatively regulates cell cycle via SC1 Ceramide signalling Regulated proteolysis of p75NTR NFG and proNGF binds to p75NTR NADE modulates death signalling NRIF signals cell death from the nucleus NRIF signals cell death from the nucleus p75NTR recruits signalling complexes p75NTR recruits signalling complexes NF-kB is activated and signals survival Axonal growth stimulation	Pathway 2 Golgi Associated Vesicle Biogenesis	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols SNCA and SNCAIP	Name 1 synuclein alpha	Name2 synuclein alpha interacting protein	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Amyloid fiber formation	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and COLEC11	Name 1 synuclein alpha	Name2 collectin subfamily member 11	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Lectin pathway of complement activation Initial triggering of complement Scavenging by Class A Receptors	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and AGO2	Name 1 synuclein alpha	Name2 argonaute RISC catalytic component 2	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Pre-NOTCH Transcription and Translation MicroRNA (miRNA) biogenesis Ca2+ pathway Small interfering RNA (siRNA) biogenesis Post-transcriptional silencing by small RNAs Transcriptional regulation by small RNAs TP53 Regulates Metabolic Genes MAPK6/MAPK4 signaling Regulation of RUNX1 Expression and Activity Regulation of PTEN mRNA translation Competing endogenous RNAs (ceRNAs) regulate PTEN translation Transcriptional Regulation by MECP2 Transcriptional Regulation by MECP2 Estrogen-dependent gene expression Regulation of MECP2 expression and activity NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux Nuclear events stimulated by ALK signaling in cancer Regulation of CDH11 mRNA translation by microRNAs Regulation of CDH11 mRNA translation by microRNAs Regulation of CDH1 mRNA translation by microRNAs Regulation of NPAS4 mRNA translation M-decay: degradation of maternal mRNAs by maternally stored factors Regulation of MITF-M-dependent genes involved in apoptosis TGFBR3 expression Regulation of PD-L1(CD274) translation	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and LRFN2	Name 1 synuclein alpha	Name2 leucine rich repeat and fibronectin type III domain containing 2	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Synaptic adhesion-like molecules	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and OSBPL7	Name 1 synuclein alpha	Name2 oxysterol binding protein like 7	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Synthesis of bile acids and bile salts	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and PIP5K1B	Name 1 synuclein alpha	Name2 phosphatidylinositol-4-phosphate 5-kinase type 1 beta	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Synthesis of PIPs at the plasma membrane WNT mediated activation of DVL PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and PSD3	Name 1 synuclein alpha	Name2 pleckstrin and Sec7 domain containing 3	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and TH	Name 1 synuclein alpha	Name2 tyrosine hydroxylase	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Catecholamine biosynthesis	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2 Phenylalanine Tyrosine Sapropterin Metyrosine 3-Tyrosine L-erythro-7,8-dihydrobiopterin	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2 Primary torsion dystonia (PTD)
Novel Novel	Symbols EPB41L1 and STARD13	Name 1 erythrocyte membrane protein band 4.1 like 1	Name2 StAR related lipid transfer domain containing 13	Pathway 1 Trafficking of AMPA receptors Neurexins and neuroligins Sensory processing of sound by inner hair cells of the cochlea Sensory processing of sound by outer hair cells of the cochlea	Pathway 2 RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols FOS and CENPO	Name 1 Fos proto-oncogene, AP-1 transcription factor subunit	Name2 centromere protein O	Pathway 1 Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) FCERI mediated MAPK activation Activation of the AP-1 family of transcription factors Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes Estrogen-dependent gene expression NGF-stimulated transcription NGF-stimulated transcription Estrogen-dependent nuclear events downstream of ESR-membrane signaling NPAS4 regulates expression of target genes Regulation of PD-L1(CD274) transcription	Pathway 2 Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion RHO GTPases Activate Formins Deposition of new CENPA-containing nucleosomes at the centromere Mitotic Prometaphase EML4 and NUDC in mitotic spindle formation	Drugs 1 Pseudoephedrine Nandrolone decanoate Nadroparin	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols RELA and HMGA2	Name 1 RELA proto-oncogene, NF-kB subunit	Name2 high mobility group AT-hook 2	Pathway 1 Activation of NF-kappaB in B cells RIP-mediated NFkB activation via ZBP1 Regulated proteolysis of p75NTR Downstream TCR signaling NF-kB is activated and signals survival Senescence-Associated Secretory Phenotype (SASP) FCERI mediated NF-kB activation DEx/H-box helicases activate type I IFN and inflammatory cytokines production PKMTs methylate histone lysines Transcriptional regulation of white adipocyte differentiation TAK1-dependent IKK and NF-kappa-B activation Interleukin-1 processing SUMOylation of immune response proteins IkBA variant leads to EDA-ID Dectin-1 mediated noncanonical NF-kB signaling CLEC7A (Dectin-1) signaling CD209 (DC-SIGN) signaling CLEC7A/inflammasome pathway The NLRP3 inflammasome Transcriptional Regulation by VENTX Interleukin-1 signaling TRAF6 mediated NF-kB activation Purinergic signaling in leishmaniasis infection SARS-CoV-1 activates/modulates innate immune responses Regulation of NFE2L2 gene expression Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Regulation of PD-L1(CD274) transcription	Pathway 2 Formation of Senescence-Associated Heterochromatin Foci (SAHF)	Drugs 1 Glucosamine Dimethyl fumarate SC-236	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols RELA and SUOX	Name 1 RELA proto-oncogene, NF-kB subunit	Name2 sulfite oxidase	Pathway 1 Activation of NF-kappaB in B cells RIP-mediated NFkB activation via ZBP1 Regulated proteolysis of p75NTR Downstream TCR signaling NF-kB is activated and signals survival Senescence-Associated Secretory Phenotype (SASP) FCERI mediated NF-kB activation DEx/H-box helicases activate type I IFN and inflammatory cytokines production PKMTs methylate histone lysines Transcriptional regulation of white adipocyte differentiation TAK1-dependent IKK and NF-kappa-B activation Interleukin-1 processing SUMOylation of immune response proteins IkBA variant leads to EDA-ID Dectin-1 mediated noncanonical NF-kB signaling CLEC7A (Dectin-1) signaling CD209 (DC-SIGN) signaling CLEC7A/inflammasome pathway The NLRP3 inflammasome Transcriptional Regulation by VENTX Interleukin-1 signaling TRAF6 mediated NF-kB activation Purinergic signaling in leishmaniasis infection SARS-CoV-1 activates/modulates innate immune responses Regulation of NFE2L2 gene expression Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Regulation of PD-L1(CD274) transcription	Pathway 2 Sulfide oxidation to sulfate	Drugs 1 Glucosamine Dimethyl fumarate SC-236	Drugs 2 {[2-Amino-4-oxo-6,7-di(sulfanyl-κS)-3,5,5a,8,9a,10-hexahydro-4H-pyrano[3,2-g]pteridin-8-yl]methyl dihydrogenato(2-) phosphate}(dioxo)sulfanylmolybdenum	Diseases 1	Diseases 2
Novel Novel	Symbols NOP2 and PVT1	Name 1 NOP2 nucleolar protein	Name2 Pvt1 oncogene	Pathway 1 rRNA modification in the nucleus and cytosol TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols AKT2 and PNPLA3	Name 1 AKT serine/threonine kinase 2	Name2 patatin like domain 3, 1-acylglycerol-3-phosphate O-acyltransferase	Pathway 1 Activation of BAD and translocation to mitochondria PIP3 activates AKT signaling PIP3 activates AKT signaling Downregulation of ERBB2:ERBB3 signaling Translocation of SLC2A4 (GLUT4) to the plasma membrane Activation of AKT2 PDE3B signalling Inhibition of TSC complex formation by PKB AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network AKT-mediated inactivation of FOXO1A Deactivation of the beta-catenin transactivating complex CD28 dependent PI3K/Akt signaling Co-inhibition by CTLA4 G beta:gamma signalling through PI3Kgamma VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry RAB GEFs exchange GTP for GDP on RABs RUNX2 regulates genes involved in cell migration Regulation of PTEN stability and activity FLT3 Signaling Regulation of localization of FOXO transcription factors Estrogen-dependent nuclear events downstream of ESR-membrane signaling KEAP1-NFE2L2 pathway SARS-CoV-2 targets host intracellular signalling and regulatory pathways Regulation of MITF-M-dependent genes involved in pigmentation	Pathway 2 Acyl chain remodeling of DAG and TAG	Drugs 1 N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	Drugs 2	Diseases 1 Ovarian cancer Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy	Diseases 2
Novel Novel	Symbols AKT2 and CHUK	Name 1 AKT serine/threonine kinase 2	Name2 component of inhibitor of nuclear factor kappa B kinase complex	Pathway 1 Activation of BAD and translocation to mitochondria PIP3 activates AKT signaling PIP3 activates AKT signaling Downregulation of ERBB2:ERBB3 signaling Translocation of SLC2A4 (GLUT4) to the plasma membrane Activation of AKT2 PDE3B signalling Inhibition of TSC complex formation by PKB AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network AKT-mediated inactivation of FOXO1A Deactivation of the beta-catenin transactivating complex CD28 dependent PI3K/Akt signaling Co-inhibition by CTLA4 G beta:gamma signalling through PI3Kgamma VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry RAB GEFs exchange GTP for GDP on RABs RUNX2 regulates genes involved in cell migration Regulation of PTEN stability and activity FLT3 Signaling Regulation of localization of FOXO transcription factors Estrogen-dependent nuclear events downstream of ESR-membrane signaling KEAP1-NFE2L2 pathway SARS-CoV-2 targets host intracellular signalling and regulatory pathways Regulation of MITF-M-dependent genes involved in pigmentation	Pathway 2 Activation of NF-kappaB in B cells Activation of NF-kappaB in B cells ER-Phagosome pathway NOD1/2 Signaling Pathway TICAM1, RIP1-mediated IKK complex recruitment RIP-mediated NFkB activation via ZBP1 AKT phosphorylates targets in the cytosol Downstream TCR signaling FCERI mediated NF-kB activation TAK1-dependent IKK and NF-kappa-B activation Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway IKBKB deficiency causes SCID IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) IkBA variant leads to EDA-ID Dectin-1 mediated noncanonical NF-kB signaling CLEC7A (Dectin-1) signaling Constitutive Signaling by AKT1 E17K in Cancer NIK-->noncanonical NF-kB signaling MAP3K8 (TPL2)-dependent MAPK1/3 activation Interleukin-1 signaling TRAF6 mediated NF-kB activation NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 IRAK1 recruits IKK complex IKK complex recruitment mediated by RIP1 SARS-CoV-2 activates/modulates innate and adaptive immune responses IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation Regulation of NF-kappa B signaling PKR-mediated signaling SLC15A4:TASL-dependent IRF5 activation Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Modulation of host responses by IFN-stimulated genes	Drugs 1 N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	Drugs 2 Aminosalicylic acid Mesalazine Acetylcysteine	Diseases 1 Ovarian cancer Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy	Diseases 2 Cocoon syndrome
Novel Novel	Symbols ETS2 and POU5F1	Name 1 ETS proto-oncogene 2, transcription factor	Name2 POU class 5 homeobox 1	Pathway 1 Oncogene Induced Senescence	Pathway 2 POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation Transcriptional regulation of pluripotent stem cells Germ layer formation at gastrulation Formation of the anterior neural plate Specification of primordial germ cells Specification of the neural plate border	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols ETS2 and FOCAD	Name 1 ETS proto-oncogene 2, transcription factor	Name2 focadhesin	Pathway 1 Oncogene Induced Senescence	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols CTTN and CTTNBP2	Name 1 cortactin	Name2 cortactin binding protein 2	Pathway 1 RHO GTPases activate PAKs Clathrin-mediated endocytosis	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols NGFR and NTRK2	Name 1 nerve growth factor receptor	Name2 neurotrophic receptor tyrosine kinase 2	Pathway 1 Axonal growth inhibition (RHOA activation) NRAGE signals death through JNK p75NTR negatively regulates cell cycle via SC1 Ceramide signalling Regulated proteolysis of p75NTR NFG and proNGF binds to p75NTR NADE modulates death signalling NRIF signals cell death from the nucleus NRIF signals cell death from the nucleus p75NTR recruits signalling complexes p75NTR recruits signalling complexes NF-kB is activated and signals survival Axonal growth stimulation	Pathway 2 PIP3 activates AKT signaling NGF-independant TRKA activation Constitutive Signaling by Aberrant PI3K in Cancer PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling BDNF activates NTRK2 (TRKB) signaling NTF3 activates NTRK2 (TRKB) signaling NTF4 activates NTRK2 (TRKB) signaling Activated NTRK2 signals through RAS Activated NTRK2 signals through PLCG1 Activated NTRK2 signals through PLCG1 Activated NTRK2 signals through PI3K Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK2 signals through FYN NTRK2 activates RAC1 NTRK2 activates RAC1 Activated NTRK2 signals through CDK5	Drugs 1	Drugs 2 Amitriptyline Esketamine Entrectinib Fostamatinib Larotrectinib	Diseases 1	Diseases 2 Neuroblastoma
Novel	Symbols NGFR and SORT1	Name 1 nerve growth factor receptor	Name2 sortilin 1	Pathway 1 Axonal growth inhibition (RHOA activation) NRAGE signals death through JNK p75NTR negatively regulates cell cycle via SC1 Ceramide signalling Regulated proteolysis of p75NTR NFG and proNGF binds to p75NTR NADE modulates death signalling NRIF signals cell death from the nucleus NRIF signals cell death from the nucleus p75NTR recruits signalling complexes p75NTR recruits signalling complexes NF-kB is activated and signals survival Axonal growth stimulation	Pathway 2 Golgi Associated Vesicle Biogenesis	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols SNCA and SNCAIP	Name 1 synuclein alpha	Name2 synuclein alpha interacting protein	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Amyloid fiber formation	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and COLEC11	Name 1 synuclein alpha	Name2 collectin subfamily member 11	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Lectin pathway of complement activation Initial triggering of complement Scavenging by Class A Receptors	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and AGO2	Name 1 synuclein alpha	Name2 argonaute RISC catalytic component 2	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Pre-NOTCH Transcription and Translation MicroRNA (miRNA) biogenesis Ca2+ pathway Small interfering RNA (siRNA) biogenesis Post-transcriptional silencing by small RNAs Transcriptional regulation by small RNAs TP53 Regulates Metabolic Genes MAPK6/MAPK4 signaling Regulation of RUNX1 Expression and Activity Regulation of PTEN mRNA translation Competing endogenous RNAs (ceRNAs) regulate PTEN translation Transcriptional Regulation by MECP2 Transcriptional Regulation by MECP2 Estrogen-dependent gene expression Regulation of MECP2 expression and activity NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux Nuclear events stimulated by ALK signaling in cancer Regulation of CDH11 mRNA translation by microRNAs Regulation of CDH11 mRNA translation by microRNAs Regulation of CDH1 mRNA translation by microRNAs Regulation of NPAS4 mRNA translation M-decay: degradation of maternal mRNAs by maternally stored factors Regulation of MITF-M-dependent genes involved in apoptosis TGFBR3 expression Regulation of PD-L1(CD274) translation	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and LRFN2	Name 1 synuclein alpha	Name2 leucine rich repeat and fibronectin type III domain containing 2	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Synaptic adhesion-like molecules	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and OSBPL7	Name 1 synuclein alpha	Name2 oxysterol binding protein like 7	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Synthesis of bile acids and bile salts	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and PIP5K1B	Name 1 synuclein alpha	Name2 phosphatidylinositol-4-phosphate 5-kinase type 1 beta	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Synthesis of PIPs at the plasma membrane WNT mediated activation of DVL PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and PSD3	Name 1 synuclein alpha	Name2 pleckstrin and Sec7 domain containing 3	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and TH	Name 1 synuclein alpha	Name2 tyrosine hydroxylase	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Catecholamine biosynthesis	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2 Phenylalanine Tyrosine Sapropterin Metyrosine 3-Tyrosine L-erythro-7,8-dihydrobiopterin	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2 Primary torsion dystonia (PTD)
Novel	Symbols EPB41L1 and STARD13	Name 1 erythrocyte membrane protein band 4.1 like 1	Name2 StAR related lipid transfer domain containing 13	Pathway 1 Trafficking of AMPA receptors Neurexins and neuroligins Sensory processing of sound by inner hair cells of the cochlea Sensory processing of sound by outer hair cells of the cochlea	Pathway 2 RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols FOS and CENPO	Name 1 Fos proto-oncogene, AP-1 transcription factor subunit	Name2 centromere protein O	Pathway 1 Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) FCERI mediated MAPK activation Activation of the AP-1 family of transcription factors Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes Estrogen-dependent gene expression NGF-stimulated transcription NGF-stimulated transcription Estrogen-dependent nuclear events downstream of ESR-membrane signaling NPAS4 regulates expression of target genes Regulation of PD-L1(CD274) transcription	Pathway 2 Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion RHO GTPases Activate Formins Deposition of new CENPA-containing nucleosomes at the centromere Mitotic Prometaphase EML4 and NUDC in mitotic spindle formation	Drugs 1 Pseudoephedrine Nandrolone decanoate Nadroparin	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols RELA and HMGA2	Name 1 RELA proto-oncogene, NF-kB subunit	Name2 high mobility group AT-hook 2	Pathway 1 Activation of NF-kappaB in B cells RIP-mediated NFkB activation via ZBP1 Regulated proteolysis of p75NTR Downstream TCR signaling NF-kB is activated and signals survival Senescence-Associated Secretory Phenotype (SASP) FCERI mediated NF-kB activation DEx/H-box helicases activate type I IFN and inflammatory cytokines production PKMTs methylate histone lysines Transcriptional regulation of white adipocyte differentiation TAK1-dependent IKK and NF-kappa-B activation Interleukin-1 processing SUMOylation of immune response proteins IkBA variant leads to EDA-ID Dectin-1 mediated noncanonical NF-kB signaling CLEC7A (Dectin-1) signaling CD209 (DC-SIGN) signaling CLEC7A/inflammasome pathway The NLRP3 inflammasome Transcriptional Regulation by VENTX Interleukin-1 signaling TRAF6 mediated NF-kB activation Purinergic signaling in leishmaniasis infection SARS-CoV-1 activates/modulates innate immune responses Regulation of NFE2L2 gene expression Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Regulation of PD-L1(CD274) transcription	Pathway 2 Formation of Senescence-Associated Heterochromatin Foci (SAHF)	Drugs 1 Glucosamine Dimethyl fumarate SC-236	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols RELA and SUOX	Name 1 RELA proto-oncogene, NF-kB subunit	Name2 sulfite oxidase	Pathway 1 Activation of NF-kappaB in B cells RIP-mediated NFkB activation via ZBP1 Regulated proteolysis of p75NTR Downstream TCR signaling NF-kB is activated and signals survival Senescence-Associated Secretory Phenotype (SASP) FCERI mediated NF-kB activation DEx/H-box helicases activate type I IFN and inflammatory cytokines production PKMTs methylate histone lysines Transcriptional regulation of white adipocyte differentiation TAK1-dependent IKK and NF-kappa-B activation Interleukin-1 processing SUMOylation of immune response proteins IkBA variant leads to EDA-ID Dectin-1 mediated noncanonical NF-kB signaling CLEC7A (Dectin-1) signaling CD209 (DC-SIGN) signaling CLEC7A/inflammasome pathway The NLRP3 inflammasome Transcriptional Regulation by VENTX Interleukin-1 signaling TRAF6 mediated NF-kB activation Purinergic signaling in leishmaniasis infection SARS-CoV-1 activates/modulates innate immune responses Regulation of NFE2L2 gene expression Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Regulation of PD-L1(CD274) transcription	Pathway 2 Sulfide oxidation to sulfate	Drugs 1 Glucosamine Dimethyl fumarate SC-236	Drugs 2 {[2-Amino-4-oxo-6,7-di(sulfanyl-κS)-3,5,5a,8,9a,10-hexahydro-4H-pyrano[3,2-g]pteridin-8-yl]methyl dihydrogenato(2-) phosphate}(dioxo)sulfanylmolybdenum	Diseases 1	Diseases 2
Novel	Symbols NOP2 and PVT1	Name 1 NOP2 nucleolar protein	Name2 Pvt1 oncogene	Pathway 1 rRNA modification in the nucleus and cytosol TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols AKT2 and PNPLA3	Name 1 AKT serine/threonine kinase 2	Name2 patatin like domain 3, 1-acylglycerol-3-phosphate O-acyltransferase	Pathway 1 Activation of BAD and translocation to mitochondria PIP3 activates AKT signaling PIP3 activates AKT signaling Downregulation of ERBB2:ERBB3 signaling Translocation of SLC2A4 (GLUT4) to the plasma membrane Activation of AKT2 PDE3B signalling Inhibition of TSC complex formation by PKB AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network AKT-mediated inactivation of FOXO1A Deactivation of the beta-catenin transactivating complex CD28 dependent PI3K/Akt signaling Co-inhibition by CTLA4 G beta:gamma signalling through PI3Kgamma VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry RAB GEFs exchange GTP for GDP on RABs RUNX2 regulates genes involved in cell migration Regulation of PTEN stability and activity FLT3 Signaling Regulation of localization of FOXO transcription factors Estrogen-dependent nuclear events downstream of ESR-membrane signaling KEAP1-NFE2L2 pathway SARS-CoV-2 targets host intracellular signalling and regulatory pathways Regulation of MITF-M-dependent genes involved in pigmentation	Pathway 2 Acyl chain remodeling of DAG and TAG	Drugs 1 N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	Drugs 2	Diseases 1 Ovarian cancer Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy	Diseases 2
Novel	Symbols AKT2 and CHUK	Name 1 AKT serine/threonine kinase 2	Name2 component of inhibitor of nuclear factor kappa B kinase complex	Pathway 1 Activation of BAD and translocation to mitochondria PIP3 activates AKT signaling PIP3 activates AKT signaling Downregulation of ERBB2:ERBB3 signaling Translocation of SLC2A4 (GLUT4) to the plasma membrane Activation of AKT2 PDE3B signalling Inhibition of TSC complex formation by PKB AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network AKT-mediated inactivation of FOXO1A Deactivation of the beta-catenin transactivating complex CD28 dependent PI3K/Akt signaling Co-inhibition by CTLA4 G beta:gamma signalling through PI3Kgamma VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry RAB GEFs exchange GTP for GDP on RABs RUNX2 regulates genes involved in cell migration Regulation of PTEN stability and activity FLT3 Signaling Regulation of localization of FOXO transcription factors Estrogen-dependent nuclear events downstream of ESR-membrane signaling KEAP1-NFE2L2 pathway SARS-CoV-2 targets host intracellular signalling and regulatory pathways Regulation of MITF-M-dependent genes involved in pigmentation	Pathway 2 Activation of NF-kappaB in B cells Activation of NF-kappaB in B cells ER-Phagosome pathway NOD1/2 Signaling Pathway TICAM1, RIP1-mediated IKK complex recruitment RIP-mediated NFkB activation via ZBP1 AKT phosphorylates targets in the cytosol Downstream TCR signaling FCERI mediated NF-kB activation TAK1-dependent IKK and NF-kappa-B activation Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway IKBKB deficiency causes SCID IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) IkBA variant leads to EDA-ID Dectin-1 mediated noncanonical NF-kB signaling CLEC7A (Dectin-1) signaling Constitutive Signaling by AKT1 E17K in Cancer NIK-->noncanonical NF-kB signaling MAP3K8 (TPL2)-dependent MAPK1/3 activation Interleukin-1 signaling TRAF6 mediated NF-kB activation NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 IRAK1 recruits IKK complex IKK complex recruitment mediated by RIP1 SARS-CoV-2 activates/modulates innate and adaptive immune responses IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation Regulation of NF-kappa B signaling PKR-mediated signaling SLC15A4:TASL-dependent IRF5 activation Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Modulation of host responses by IFN-stimulated genes	Drugs 1 N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	Drugs 2 Aminosalicylic acid Mesalazine Acetylcysteine	Diseases 1 Ovarian cancer Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy	Diseases 2 Cocoon syndrome
Novel	Symbols ETS2 and POU5F1	Name 1 ETS proto-oncogene 2, transcription factor	Name2 POU class 5 homeobox 1	Pathway 1 Oncogene Induced Senescence	Pathway 2 POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation Transcriptional regulation of pluripotent stem cells Germ layer formation at gastrulation Formation of the anterior neural plate Specification of primordial germ cells Specification of the neural plate border	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols ETS2 and FOCAD	Name 1 ETS proto-oncogene 2, transcription factor	Name2 focadhesin	Pathway 1 Oncogene Induced Senescence	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols CTTN and CTTNBP2	Name 1 cortactin	Name2 cortactin binding protein 2	Pathway 1 RHO GTPases activate PAKs Clathrin-mediated endocytosis	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2

Page 27 out of 58 pages

Search Results : Diabetes